GlassScriptPhysician profile
Ilan S Levinson
NPI 1982625000
$14,350.01
in general payments reported to CMS, 2019-2025
33 companies · $2,616 in 2025
The $2,616 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,592 · 2021: $2,084 · 2022: $1,900 · 2023: $2,106 · 2024: $2,579 · 2025: $2,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,990 · Consulting Fee: $200 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,989.66 |
| Consulting Fee | $200.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,763.57 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $1,559.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $1,439.47 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $1,406.56 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,120.26 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $909.45 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $872.25 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $495.16 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $474.55 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $433.12 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $430.20 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $390.38 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $297.33 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $250.79 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $215.65 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
| Corium, LLC | $192.76 | 2022-2025 | Azstarys |
| Eisai INC. | $147.98 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $119.33 | 2022-2023 | Jornay Pm |
| Indivior INC. | $114.68 | 2020-2022 | |
| Noven Therapeutics, LLC | $95.63 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.30 | 2021-2023 | Belsomra |
| Shire North American Group INC | $63.42 | 2019 | |
| Bausch Health US, LLC | $60.72 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $43.87 | 2020 | |
| Neos Therapeutics, LP | $40.78 | 2022-2023 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $23.02 | 2022 | |
| Neuronetics, INC. | $22.03 | 2019 | |
| Biogen, INC. | $20.63 | 2022 | |
| Bioxcel Therapeutics, INC. | $16.78 | 2024 | Igalmi |
| Azurity Pharmaceuticals, INC. | $14.78 | 2022 | |
| Braeburn INC. | $14.40 | 2025 | Brixadi |
| Gilead Sciences, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.